Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Genomic Health made its Oncotype DX prostate cancer test available recently after a presentation of a positive clinical validation study by the University of California, San Francisco, at this year’s American Urological Association annual meeting.
The Center for Phlebotomy Education is conducting a three-day seminar for those who train or manage phlebotomists. It will take place Nov. 6–8 at the Brown Hotel in Louisville, Ky. The staff of the Center for Phlebotomy Education will conduct the sessions. They are program administrator Catherine Ernst, RN, PBT(ASCP); program coordinator Lisa Steinam, PBT(ASCP); and executive director Dennis J. Ernst, MT(ASCP).
Helmer Scientific’s i.Series and Horizon Series under counter refrigerators and freezers are available in ADA-compatible models. These models are designed to fit under 34-inch ADA-compliant counters and offer chamber temperature uniformity with quick recovery, bacteria-resistant powder coating, and a self-closing door with magnetic latch.
Qiagen is expanding its next-generation sequencing portfolio of nine GeneRead DNAseq panels to about 20 during the course of this year. Qiagen is leveraging its molecular content and assay portfolio to create these new gene panels for targeted NGS analysis based on the GeneGlobe portfolio of more than 60,000 annotated molecular assays.
Primera Technology now offers its chemical- , temperature- , and abrasion-resistant TuffCoat 2 (TC2) high-performance ink ribbons for its Signature Slide Printer. The new ribbon formulations were developed specifically to provide superior performance in pathology, histology, cytology, and other types of laboratory applications.
The FDA has approved GlaxoSmithKline’s Tafinlar (dabrafenib) and Mekinist (trametinib) oral oncology treatments. Tafinlar is indicated as a single-agent oral treatment for unresectable melanoma or metastatic melanoma in adult patients with BRAF V600E mutation.
Milestone Medical’s BoneStation is a dedicated system for standardizing fixation and decalcification of bone specimens. Users can optimize molecular testing results with increased RNA yield from routine cases by combining less aggressive decalcifying solutions with BoneStation’s controlled agitation and temperature management.
Immunodiagnostic Systems has received FDA clearance for its 1,25-dihydroxy vitamin D assay for use on the IDS-iSys system.
The vitamin D test is used to measure 1,25-dihydroxy vitamin D deficiency, which is associated with renal disease and used in the diagnosis of disorders in the metabolism of 25-hydroxyvitamin D and phosphate.
Gold Standard Diagnostics’ new Line Immunoassay technology for Lyme confirmation testing gives clinical laboratories an FDA-cleared option for serological confirmation testing for Lyme disease according to the CDC-recommended two-step process.
Randox Laboratories and Aterovax have announced a strategic partnership to commercialize Aterovax’s secreted phospholipase A2 (sPLA2) biomarker for the assessment of cardiovascular risk.
